RU93043875A - 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения - Google Patents

1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения

Info

Publication number
RU93043875A
RU93043875A RU93043875/04A RU93043875A RU93043875A RU 93043875 A RU93043875 A RU 93043875A RU 93043875/04 A RU93043875/04 A RU 93043875/04A RU 93043875 A RU93043875 A RU 93043875A RU 93043875 A RU93043875 A RU 93043875A
Authority
RU
Russia
Prior art keywords
treatment
oxatiolan
fluorocytosine
hydroxymethyl
hepatitis
Prior art date
Application number
RU93043875/04A
Other languages
English (en)
Other versions
RU2116789C1 (ru
Original Assignee
Дзе Велкам Фаундейшн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Дзе Велкам Фаундейшн Лимитед filed Critical Дзе Велкам Фаундейшн Лимитед
Publication of RU93043875A publication Critical patent/RU93043875A/ru
Application granted granted Critical
Publication of RU2116789C1 publication Critical patent/RU2116789C1/ru

Links

Claims (1)

  1. Описывается аналог 1,3-оксатиолан нуклеозида и его приемлемое с фармацевтической точки зрения производное, полезные для лечения вирусных инфекций гепатита В и его применение. Описываются также фармацевтические композиции.
RU93043875A 1991-03-06 1992-03-05 Способ ингибирования вирусных инфекций гепатита в RU2116789C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9104741.5 1991-03-06
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides
GB9109505.9 1991-05-02

Publications (2)

Publication Number Publication Date
RU93043875A true RU93043875A (ru) 1997-02-20
RU2116789C1 RU2116789C1 (ru) 1998-08-10

Family

ID=26298535

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93043875A RU2116789C1 (ru) 1991-03-06 1992-03-05 Способ ингибирования вирусных инфекций гепатита в

Country Status (21)

Country Link
EP (3) EP0574487B1 (ru)
JP (5) JP3479068B2 (ru)
KR (1) KR100270806B1 (ru)
AT (2) ATE361293T1 (ru)
AU (1) AU662130B2 (ru)
CA (1) CA2105486C (ru)
CZ (1) CZ282747B6 (ru)
DE (2) DE69233693T2 (ru)
DK (2) DK0574487T3 (ru)
ES (2) ES2286072T3 (ru)
HU (1) HUT64844A (ru)
IE (1) IE920701A1 (ru)
IL (1) IL101144A (ru)
MX (1) MX9203213A (ru)
NZ (1) NZ264621A (ru)
PT (1) PT100198B (ru)
RU (1) RU2116789C1 (ru)
SK (1) SK279542B6 (ru)
TW (1) TW201268B (ru)
UA (1) UA54364C2 (ru)
WO (1) WO1992015308A1 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
DE69233693T2 (de) * 1991-03-06 2008-01-24 Emory University Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6071922A (en) * 1997-03-19 2000-06-06 Emory University Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
MXPA01001507A (es) 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
RU2439069C2 (ru) 1998-08-12 2012-01-10 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиолановых нуклеозидов
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2004024095A2 (en) 2002-09-13 2004-03-25 Idenix (Cayman) Limited ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
DE69233693T2 (de) * 1991-03-06 2008-01-24 Emory University Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B

Similar Documents

Publication Publication Date Title
RU93043875A (ru) 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения
CA2105486A1 (en) Therapeutic nucleosides
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
RU93045710A (ru) Противовирусная нуклеозидная композиция, способ ее получения и способ лечения
ITMI931522A0 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
IL101836A (en) Pharmaceutical compositions containing 1, 3-oxathiolane nucleoside analogues
DE19875016I2 (de) Nukleosidanalogen enthaltende Antiviren-Zubereitungen.
CA2143204A1 (en) Use of Dideoxy Nucleoside Analogues in the Treatment of Viral Infections
NO931246D0 (no) Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)
DE69434805D1 (de) Ringerweiterte Nukleoside und Nukleotide
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
IT1289238B1 (it) Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
MY137298A (en) Therapeutic nucleosides
AU4829190A (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
RU93058386A (ru) Противовирусная комбинация, содержащая неуклеозидный аналог, фармацевтическая композиция, способ лечения
RU93058540A (ru) Производные 2-гидроксиметил-5-/5-фторцитозин-1-ил/-1,3-оксатиолан, фармкомпозиция, способы его получения, применение, способы лечения
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
KR960021043A (ko) 스코폴레틴을 포함하는 b형 간염 치료제
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
RU93046287A (ru) Аминодиольные ингибиторы протеза
ZA932271B (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)